International Clinical Trial: Application research on the use of Disitamab Vedotin combined with Toripalimab for bladder preservation in high-risk NMIBC patients with HER2 overexpression

Geneva, May 29 -- International Clinical Trials Registry received information related to the study (ChiCTR2600125168) titled 'Application research on the use of Disitamab Vedotin combined with Toripalimab for bladder preservation in high-risk NMIBC patients with HER2 overexpression' on May 21.

Study Type: Interventional study

Study Design: Single arm

Primary Sponsor: ZhangZhou Municipal Hospital of Fujian province

Condition: High-risk non-muscle-invasive bladder urothelial carcinoma

Recruitment Status: Not Recruiting

Phase: 2

Date of First Enrollment: 2026-06-01

Target Sample Size: Experimental group(HR-NMIBC):39;

Countries of Recruitment: China

To know more, visit https://www.chictr.org.cn/showproj.html?proj=319037

Publi...